IL225483A0 - The compositions and methods for the treatment of neoplasia - Google Patents

The compositions and methods for the treatment of neoplasia

Info

Publication number
IL225483A0
IL225483A0 IL225483A IL22548313A IL225483A0 IL 225483 A0 IL225483 A0 IL 225483A0 IL 225483 A IL225483 A IL 225483A IL 22548313 A IL22548313 A IL 22548313A IL 225483 A0 IL225483 A0 IL 225483A0
Authority
IL
Israel
Prior art keywords
compositions
methods
treating neoplasia
neoplasia
treating
Prior art date
Application number
IL225483A
Other languages
English (en)
Hebrew (he)
Original Assignee
Zestagen S A
Katerina Sidera
Evangelia Patsavoudi
Avgi Mamalaki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zestagen S A, Katerina Sidera, Evangelia Patsavoudi, Avgi Mamalaki filed Critical Zestagen S A
Publication of IL225483A0 publication Critical patent/IL225483A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL225483A 2010-09-27 2013-03-24 The compositions and methods for the treatment of neoplasia IL225483A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38676410P 2010-09-27 2010-09-27
PCT/EP2011/066791 WO2012041863A1 (en) 2010-09-27 2011-09-27 Compositions and methods for treating neoplasia

Publications (1)

Publication Number Publication Date
IL225483A0 true IL225483A0 (en) 2013-06-27

Family

ID=44675608

Family Applications (1)

Application Number Title Priority Date Filing Date
IL225483A IL225483A0 (en) 2010-09-27 2013-03-24 The compositions and methods for the treatment of neoplasia

Country Status (12)

Country Link
US (2) US9115192B2 (cg-RX-API-DMAC10.html)
EP (1) EP2621947A1 (cg-RX-API-DMAC10.html)
JP (1) JP5946459B2 (cg-RX-API-DMAC10.html)
KR (1) KR20140016240A (cg-RX-API-DMAC10.html)
CN (1) CN103459420B (cg-RX-API-DMAC10.html)
AU (1) AU2011310664B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013007327A2 (cg-RX-API-DMAC10.html)
CA (1) CA2812644A1 (cg-RX-API-DMAC10.html)
IL (1) IL225483A0 (cg-RX-API-DMAC10.html)
MX (1) MX2013003561A (cg-RX-API-DMAC10.html)
SG (1) SG189095A1 (cg-RX-API-DMAC10.html)
WO (1) WO2012041863A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI718086B (zh) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
JP6488520B2 (ja) * 2013-08-20 2019-03-27 国立研究開発法人科学技術振興機構 ヒト抗体κ型軽鎖複合体含有組成物及びその製造方法
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
US10877024B2 (en) * 2015-05-12 2020-12-29 Superlab Far East Limited Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
KR20070094890A (ko) * 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 ａｄｄｌ 항체 및 그 용도

Also Published As

Publication number Publication date
BR112013007327A2 (pt) 2017-07-04
US20160075771A1 (en) 2016-03-17
US20130280244A1 (en) 2013-10-24
KR20140016240A (ko) 2014-02-07
SG189095A1 (en) 2013-05-31
MX2013003561A (es) 2013-09-02
CN103459420B (zh) 2016-09-28
CA2812644A1 (en) 2012-04-05
WO2012041863A1 (en) 2012-04-05
AU2011310664A1 (en) 2013-05-09
AU2011310664B2 (en) 2016-02-18
JP2013541944A (ja) 2013-11-21
US9115192B2 (en) 2015-08-25
JP5946459B2 (ja) 2016-07-06
CN103459420A (zh) 2013-12-18
EP2621947A1 (en) 2013-08-07
US9328161B2 (en) 2016-05-03

Similar Documents

Publication Publication Date Title
IL253870A0 (en) Certain amino-pyrimidines, their assemblies, and methods of using them
EP2655334A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
IL222993A0 (en) Compositions and methods for treating neoplasia, inflammatory disease and otheir disoreders
SG10201500124VA (en) Methods and Compositions for Treating Cancer
EP2523944A4 (en) COMPOUNDS AND COMPOSITIONS FOR IMPROVING COGNITION, METHODS OF MAKING THE SAME, AND METHODS OF TREATMENT
ZA201303423B (en) Compositions and methods for treating myelofibrosis
SG2014010706A (en) Method and composition
IL222465A0 (en) Certain amino-pyridazines, compositions thereof, and methods for their use
IL238416A0 (en) Preparations and methods for the treatment of diseases caused by protein pathology
GB201016001D0 (en) Composition and method
IL219610A0 (en) Compositions and methods for treating colitis
EP2429584A4 (en) TREATMENT PROCEDURE AND COMPOSITIONS
PH12013500698A1 (en) Hair-mending compositions and associated methods
EP2590674A4 (en) COMPOSITIONS AND METHODS FOR INFLUENZA TREATMENT
GB201003531D0 (en) Composition and method
GB201018650D0 (en) Methods and compositions
GB201008364D0 (en) Composition and method
ZA201305497B (en) Methods and compositions for preventing and treating osteoarthritis
GB201008843D0 (en) Method and composition
PL2606032T3 (pl) Kompozycja i sposoby terapii glejakaep
GB201118532D0 (en) Absorbent composition
IL225959A0 (en) Methods and preparations for diagnosis and treatment @ בסרטן
EP2632494A4 (en) METHODS AND COMPOSITIONS FOR EVALUATING AND TREATING CANCER
IL220796A0 (en) Compositions and methods for treating gliblastoma gbm
GB201009767D0 (en) Compositions and methods